<- Go Home
AstraZeneca AB
AstraZeneca AB researches, develops, manufactures, and markets medicines for cardiovascular, metabolic, and kidney diseases; and cancer, and infection and vaccines, as well as diseases of the respiratory tract, inflammation, and autoimmunity. AstraZeneca AB was formerly known as Astra AB and changed its name to AstraZeneca AB in April 1999. The company was incorporated in 1913 and is based in Södertälje, Sweden with strategic research centres in Sweden, the United States, and the United Kingdom. AstraZeneca AB operates as a subsidiary of AstraZeneca Treasury Limited.
Market Cap
N/A
Volume
N/A
Cash and Equivalents
$11.8B
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$48.4B
Profit Margin
N/A
52 Week High
N/A
52 Week Low
N/A
Dividend
N/A
Price / Book Value
N/A
Price / Earnings
N/A
Price / Tangible Book Value
N/A
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
$13.9B
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$22.5B
Debt
$933.0M
Equity
$54.9B
Revenue
$57.2B
Unlevered FCF
N/A
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium